Fluor to Design and Build $2 Billion Diabetes API Manufacturing Facility for Novo Nordisk in North Carolina
21 December 2016 - 8:33AM
Business Wire
Fluor Corporation (NYSE: FLR) has been awarded an engineering,
procurement, construction and construction management contract by
Novo Nordisk for its new $2 billion diabetes Active Pharmaceutical
Ingredient (API) manufacturing facility in Clayton, North Carolina.
Fluor has been providing basic design services since Novo Nordisk
announced plans for the new facility in August 2015 and now will be
executing the full scope of work. Fluor booked its $1.2 billion
value of the investment in the fourth quarter of 2016.
“Fluor is honored to have the opportunity to assist Novo Nordisk
in building this world-class facility in North Carolina to provide
modern treatments to diabetes patients,” said Juan G. Hernández,
president of Fluor’s Life Sciences and Advanced Manufacturing
business. “This project is the single largest life sciences
facility investment in North Carolina’s history, which fits well
with Fluor’s legacy of building numerous significant life sciences
and manufacturing projects in the southeast United States.”
“Novo Nordisk selected Fluor for this critical project, the
largest in our history, based on their strong safety culture,
technical competence in the life sciences industry and ability to
deliver the full scope of work,” said Morten Nielsen, senior vice
president, Novo Nordisk, and responsible for the construction of
the new facility. “We look forward to continued strong cooperation
for the success of this project.”
The new facility will measure more than 830,000 square feet, the
equivalent of nearly seven football fields, and will produce
life-saving medicines for use by patients around the world.
Nearly 2,500 craft employees and subcontractor jobs are expected
at peak construction with about 700 new jobs at the facility when
it is completed. Fluor participated in a groundbreaking event this
past spring, and its Greenville, South Carolina office is leading
the project, leveraging Fluor’s global resources as needed.
Construction is expected to be completed in mid-2019.
Fluor’s unique integrated solutions model will enable the
company to leverage its global expertise across business lines such
as power generation, as well as its staffing and construction
equipment entities, water expertise and others for this
project.
About Fluor CorporationFluor
Corporation (NYSE: FLR) is a global engineering, procurement,
fabrication, construction and maintenance company that designs,
builds and maintains capital-efficient facilities for its clients
on six continents. For more than a century, Fluor has served our
clients by delivering innovative and integrated solutions across
the globe. With headquarters in Irving, Texas, Fluor ranks 155 on
the FORTUNE 500 list with revenue of $18.1 billion in 2015 and has
more than 60,000 employees worldwide. For more information, please
visit www.fluor.com or follow us on Twitter @FluorCorp.
About Novo NordiskNovo
Nordisk is a global healthcare company with more than 90 years of
innovation and leadership in diabetes care. Headquartered in
Denmark, Novo Nordisk employs approximately 42,000 people in 75
countries and markets its products in more than 180 countries. For
more information, visit novonordisk.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161220005971/en/
Fluor CorporationMedia Relations:Brian Mershon,
469-398-7621Brett Turner, 864-281-6976orInvestor Relations:Geoff
Telfer, 469-398-7070Jason Landkamer, 469-398-7222
Fluor (NYSE:FLR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluor (NYSE:FLR)
Historical Stock Chart
From Sep 2023 to Sep 2024